Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Genecast Biotechnology Announce Partnership to Advance Cancer Diagnosis in China

Genecast Biotechnology
Posted on: 15 Sep 18
Genecast Biotechnology Announce Partnership to Advance Cancer Diagnosis in China Genecast Biotechnology of China has reached a partnership with Illumina to develop IVD kits in China using Illumina's NGS technology.

PR Newswire

BEIJING, Sept. 15, 2018

BEIJING, Sept. 15, 2018 /PRNewswire-PRWeb/ -- Genecast Biotechnology Co. Ltd. (Genecast) announced it has just reached strategic partnership agreement with the global leader in DNA sequencing and array-based technologies, Illumina. Genecast will seek to advance cancer diagnosis using Illumina's next-generation sequencing (NGS) technology. Both companies are at the forefront of their fields – Illumina in gene sequencing and Genecast in molecular testing and diagnosis of cancer – and it is hoped that the combination of these two leading companies will have far-reaching benefits for the Chinese cancer patients.

Under the partnership, Genecast will develop a cancer diagnosis system and kit specifically targeting colorectal cancer. This is the first time that an IVD kit based on Illumina NGS technology will be developed for this type of cancer in China. Additionally, Genecast will also develop a cancer diagnosis system and kit aimed at lung cancer based on Illumina's NGS technology.

Statistics have shown that lung and colorectal cancers are among the top three types of cancers in China, with more than 700,000 new cases of lung cancer and more than 400,000 new cases of colorectal cancer reported each year. Development of these two new cancer diagnosis systems will drive forward China's ability to more effectively treat these cancers using NGS based precision medicine technology.

In this IVD development, Genecast will utilize its proprietary genetic analysis tools to enable higher diagnostic accuracy. "We are very happy to announce our partnership with the global NGS-technology leader Illumina. Illumina's decision to cooperate with Genecast demonstrates its recognition of Genecast in both its development capability and commercial reach in China in the field of clinical applications of NGS technology." said Du Bo, Genecast Co-founder and CEO. "We look forward to seeing the innovative platforms developed in this cooperation to enable patients to access better medical solutions."

About Genecast Biotechnology Co. Ltd.
Genecast Biotechnology Co. Ltd. is a privately held leading precision oncology company in China. We offer well validated clinical tests to cancer patients and clinicians based on multiple technology platforms including NGS, IHC, ddPCR, microarray. etc. We are dedicated to providing patients and clinicians individualized cancer diagnosis and treatment to improve their survival and quality of life.
In addition, by leveraging our multifaceted technical approach, we actively collaborate with leading domestic and international pharmaceutical and biotech companies to develop and validate oncology biomarkers for clinical trials, treatment and companion diagnosis.
http://www.genecast.com.cn

Media Contact:
Dan Chen
Genecast Biotechnology
+(86) 134-3979-5181
chen.dan(at)genecast.com.cn

 

SOURCE Genecast Biotechnology

PR Newswire
www.prnewswire.com

Last updated on: 15/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.